eltrombopag + romiplostim

Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPO-RAs) used primarily for the treatment of chronic immune (idiopathic) thrombocytopenia (ITP) in patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Both drugs act by stimulating the thrombopoietin receptor (c-Mpl/CD110), leading to increased platelet production. Romiplostim is a peptibody that binds directly and competitively at the TPO binding site on the receptor, while eltrombopag is a small molecule that binds at a transmembrane site on the same receptor. Activation of these receptors leads to downstream signaling via JAK2/STAT5 and other pathways, resulting in proliferation of megakaryocyte progenitors and increased platelet counts. Eltrombopag is also indicated for severe aplastic anemia and hepatitis C-associated thrombocytopenia; romiplostim’s primary indication remains ITP[1][2][3][6][8].

Brand names

PromactaRevoladeNplate

Other names

TPO-RAsThrombopoietin receptor agonists